We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
Read MoreHide Full Article
Shares of small biotech Arcutis Biotherapeutics (ARQT - Free Report) have surged nearly three times in market value in the past year.
The upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.
This drug is currently approved for use in different formulations – as foam and cream – across different indications.
ARQT Stock Performance
In the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall.
Image Source: Zacks Investment Research
Zoryve – A Key Top-Line Driver for Arcutis
Since its launch, Zoryve has witnessed a strong uptake fueled by the continued growth of unit demand. In the first nine months of 2024, Arcutis recorded product revenues of $97 million, up more than 500% from the year-ago quarter figure. This has also likely contributed to the stock price soaring.
A 0.3% formulation of Zoryve cream is approved for treating plaque psoriasis in patients six years and older and for seborrheic dermatitis in patients nine years and above. In July, the FDA approved a 0.15% formulation of the cream to treat mild to moderate atopic dermatitis (AD) in adult and pediatric patients six years and older.
A 0.15% formulation of Zoryve foam is approved to treat seborrheic dermatitis in individuals aged nine years and older.
Last month, Arcutis submitted an sNDA to the FDA for Zoryve cream 0.05% to treat mild to moderate AD in children two to five years old. An sNDA is already under the agency’s review seeking approval for Zoryve foam 0.3% to treat scalp and body psoriasis, with a final decision expected in May 2025. Potential approvals for these indications will further boost revenues in 2025.
Bottom-line estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past year, shares of Castle Biosciences have surged 34.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 34.9% in the past year.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
Shares of small biotech Arcutis Biotherapeutics (ARQT - Free Report) have surged nearly three times in market value in the past year.
The upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.
This drug is currently approved for use in different formulations – as foam and cream – across different indications.
ARQT Stock Performance
In the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall.
Image Source: Zacks Investment Research
Zoryve – A Key Top-Line Driver for Arcutis
Since its launch, Zoryve has witnessed a strong uptake fueled by the continued growth of unit demand. In the first nine months of 2024, Arcutis recorded product revenues of $97 million, up more than 500% from the year-ago quarter figure. This has also likely contributed to the stock price soaring.
A 0.3% formulation of Zoryve cream is approved for treating plaque psoriasis in patients six years and older and for seborrheic dermatitis in patients nine years and above. In July, the FDA approved a 0.15% formulation of the cream to treat mild to moderate atopic dermatitis (AD) in adult and pediatric patients six years and older.
A 0.15% formulation of Zoryve foam is approved to treat seborrheic dermatitis in individuals aged nine years and older.
Last month, Arcutis submitted an sNDA to the FDA for Zoryve cream 0.05% to treat mild to moderate AD in children two to five years old. An sNDA is already under the agency’s review seeking approval for Zoryve foam 0.3% to treat scalp and body psoriasis, with a final decision expected in May 2025. Potential approvals for these indications will further boost revenues in 2025.
ARQT’s Zacks Rank
Arcutis currently carries a Zacks Rank #3 (Hold).
Arcutis Biotherapeutics, Inc. Price
Arcutis Biotherapeutics, Inc. price | Arcutis Biotherapeutics, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) , Spero Therapeutics (SPRO - Free Report) and CytomX Therapeutics (CTMX - Free Report) . While CSTL and SPRO sport a Zacks Rank #1 (Strong Buy) at present, CTMX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bottom-line estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past year, shares of Castle Biosciences have surged 34.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 34.9% in the past year.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.